-
公开(公告)号：KR101343285B1
公开(公告)日：2013-12-18
申请号：KR1020120000742
申请日：2012-01-03
Applicant: 서울대학교산학협력단
Abstract: 본발명은당뇨망막병증(diabetic retinopathy) 진단용조성물및 당뇨망막병증진단용키트에관한것이다. 또한, 본발명은당뇨망막병증진단에필요한정보를제공하기위한분석방법에관한것이다. 상기에서기술한바와같이, 본발명은당뇨망막병증을조기에진단할수 있는마커를제공함으로써, 당뇨망막병증환자에게서발현이증가또는감소한유전자또는그 단백질의발현수준을측정및 비교하여당뇨망막병증의조기진단및 질병정도를유의적으로예측또는파악할수 있다. 아울러, 본발명의마커는비침습성진단을가능하게하는바, 혈액, 뇨검사등으로간단하고유효성있는당뇨망막병증의바이오마커를이용한진단방법이개발되면가정및 일반의원에서의조기발견에매우유용할것이며, 국가적인관점에서의료비절감효과를가지고올 수있다.
-
公开(公告)号：KR1020130009205A
公开(公告)日：2013-01-23
申请号：KR1020110070123
申请日：2011-07-14
Applicant: 서울대학교산학협력단
CPC classification number: C12Q1/6883 , C12Q2600/158 , G01N33/68 , G01N2800/164 , G01N33/6893 , G01N33/5302 , G01N2800/042
Abstract: PURPOSE: A composition for diagnosing diabetic retinopathy containing an agent which measures gene or protein level of AGP(alpha-1 acid glycoprotein) or PEDF(pigment epithelium-derived factor) is provided to simply and early diagnose diabetic retinopathy. CONSTITUTION: A composition for diagnosing diabetic retinopathy contains an agent which measures mRNA or protein level of AGP or PEDF. A composition for diagnosing diabetic retinopathy contains an agent which measures mRNA or protein level of APOC1(apolipoprotein C1), APOB100(apolipoprotein B100), APOC3(apolipoprotein C3), APOB 100(apolipoprotein B100), APOC 3(apolipoprotein C3), CP(ceruloplasmin), or CFB(complement factor B). A method for providing information for diagnosing diabetic retinopathy comprises: a step of measuring gene or protein expression level of AGP or PEDF from a biological sample; and a step of comparing the expression level with the expression level of a normal control group.
Abstract translation: 目的：提供一种用于诊断糖尿病性视网膜病变的组合物，其用于测量AGP（α-1酸性糖蛋白）或PEDF（色素上皮衍生因子）的基因或蛋白质水平的试剂，以简单且早期诊断糖尿病性视网膜病变。 构成：用于诊断糖尿病性视网膜病变的组合物含有测量AGP或PEDF的mRNA或蛋白质水平的试剂。 用于诊断糖尿病视网膜病变的组合物含有测定APOC1（载脂蛋白C1），APOB100（载脂蛋白B100），APOC3（载脂蛋白C3），APOB 100（载脂蛋白B100），APOC 3（载脂蛋白C3），CP 血浆铜蓝蛋白）或CFB（补体因子B）。 提供用于诊断糖尿病性视网膜病变的信息的方法包括：从生物样品测量AGP或PEDF的基因或蛋白质表达水平的步骤; 以及将表达水平与正常对照组的表达水平进行比较的步骤。
-
公开(公告)号：KR1020130009204A
公开(公告)日：2013-01-23
申请号：KR1020110070122
申请日：2011-07-14
Applicant: 서울대학교산학협력단
CPC classification number: G01N33/6893 , G01N2800/042 , G01N2800/164 , C12Q1/6883 , G01N33/5302
Abstract: PURPOSE: A composition containing an agent which measures gene or protein level for determining development and progression of diabetic retinopathy is provided to enable non-invasive diagnosis and to early diagnose diabetic retinopathy. CONSTITUTION: A composition for diagnosing diabetic retinopathy contains an agent which measures mRNA or protein level of APOC1(apolipoprotein C1), APOB100(apolipoprotein B100), APOC3(apolipoprotein C3), VTN(vitronectin), PLG(plasminogen), HRP(histidine-rich protein), AFM(afamin) or CFB(complement factor B). A composition for diagnosing diabetic retinopathy additionally contains an agent which measures mRNA or protein level of AGP(alpha-1 acid glycoprotein), PEDF(pigment epithelium-derived factor), or CP(ceruloplasmin). The diabetic retinopathy is non-proliferative diabetic retinopathy. A method for providing information for diagnosing diabetic retinopathy comprises: a step of measuring gene or protein expression level of APOC1, APOB100, APOC3, VTN, PLG, HRP, AFM, or CFB from a biological sample; and a step of comparing the expression level with the expression level of a normal control group.
Abstract translation: 目的：提供一种含有测定基因或蛋白质水平以确定糖尿病性视网膜病变发展和进展的药物的组合物，以实现非侵入性诊断和早期诊断糖尿病性视网膜病变。 构成：用于诊断糖尿病视网膜病变的组合物含有测量APOC1（载脂蛋白C1），APOB100（载脂蛋白B100），APOC3（载脂蛋白C3），VTN（玻连蛋白），PLG（纤溶酶原），HRP（组氨酸 - 富含蛋白质），AFM（afamin）或CFB（补体因子B）。 用于诊断糖尿病性视网膜病变的组合物还含有测量AGP（α-1酸性糖蛋白），PEDF（色素上皮衍生因子）或CP（血浆铜蓝蛋白）的mRNA或蛋白质水平的试剂。 糖尿病性视网膜病变是非增殖性糖尿病性视网膜病变。 一种用于诊断糖尿病性视网膜病变的信息的方法，包括：从生物样品测量APOC1，APOB100，APOC3，VTN，PLG，HRP，AFM或CFB的基因或蛋白质表达水平的步骤; 以及将表达水平与正常对照组的表达水平进行比较的步骤。
-
公开(公告)号：KR1020150129132A
公开(公告)日：2015-11-19
申请号：KR1020140054752
申请日：2014-05-08
Applicant: 서울대학교산학협력단
CPC classification number: A23L33/10 , A23V2002/00 , A23V2200/308 , A61K31/198 , A61K35/63
Abstract: 본발명은매미껍질추출물및 이로부터분리된테아닌을포함하는항암조성물에관한것이다. 본발명에따른매미껍질추출물, 이를분획하여얻은매미껍질분획물, 또는이로부터분리되어수득되는화합물인테아닌은우수한암 세포증식억제능을나타내므로, 천연물유래의신규항암제로이용이가능하다.
Abstract translation: 本发明涉及含有蝉皮提取物和由其衍生的茶氨酸的抗癌组合物。 根据本发明的蝉皮提取物，通过分离蝉皮提取物或从蝉皮肤级分分离产生的茶氨酸获得的蝉皮组分，产生抑制癌细胞增殖的优异能力，因此能够 用作衍生自天然物质的新型抗癌药物。
-
公开(公告)号：KR101390590B1
公开(公告)日：2014-04-30
申请号：KR1020120069793
申请日：2012-06-28
Applicant: 서울대학교산학협력단
IPC: G01N33/574 , G01N33/68 , C12Q1/68
Abstract: 알파-2-안티플라스민 (Alpha-2-antiplasmin), 루미칸 (Lumican), 아포리포단백질 CIII (Apolipoprotein CIII), 알파-2-마크로글로블린 (Alpha-2-macroglobulin), 보체 C4 감마 사슬 (Complement C4 gamma chain), 라민 A/C (Lamin A/C), 연장 인자 Tu (Elongation factor Tu), 트리오스포스페이트 아이소머레이즈 (Triosephosphate isomerase) 및 카르보닉 안하드레이즈 V (Carbonic anhydrase V)으로 이루어진 군으로부터 선택되는 단백질을 포함하는 췌장암 재발 예후 예측용 마커가 개시된다. 본 발명에 의해 췌장암 환자의 수술적 치료 후, 췌장암이 재발한 환자의 혈청에서 특이적으로 과량 발현되거나 적게 발현되는 것으로 밝혀진 단백질들은 동시 항암화학 방사선 치료 전 췌장암 재발 예후를 예측할 수 있는 바이오 마커로서 유용하게 사용될 수 있다.
-
Patent Agency Ranking
公开(公告)号：KR1020140002150A
公开(公告)日：2014-01-08
申请号：KR1020120069793
申请日：2012-06-28
Applicant: 서울대학교산학협력단
IPC: G01N33/574 , G01N33/68 , C12Q1/68
CPC classification number: G01N33/57438 , C12Q1/6886 , C12Q2600/158 , G01N33/5302 , G01N33/6893 , G01N2800/067
Abstract: Disclosed is a marker for predicting the prognosis of pancreatic cancer recurrence including proteins selected from the group consisting of alpha-2-antiplasmin, lumican, apolipoprotein CIII, alpha-2-macroglobulin, complement C4 gamma chain, lamin A/C, elongation factor Tu, triosephosphate isomerase, and carbonic anhydrase V. By the present invention, the proteins known to be specifically overexpressed or downregulated in the serum of patients with recurrent pancreatic cancer after surgical treatment can be useful as a biomarker for predicting the prognosis of pancreatic cancer recurrence before concurrent chemoradiotherapy.
Abstract translation: 公开了一种用于预测胰腺癌复发的预后的标志物，包括选自下组的蛋白质：α-2-抗血纤维蛋白酶，巢蛋白，载脂蛋白CIII，α-2-巨球蛋白，补体C4γ链，层压A / C，延伸因子Tu ，三磷酸异构酶和碳酸酐酶V.通过本发明，已知在手术治疗后复发性胰腺癌患者血清中特异性过表达或下调的蛋白质可用作预测胰腺癌复发预后的生物标志物 同时放化疗
-
公开(公告)号：KR1020130079953A
公开(公告)日：2013-07-11
申请号：KR1020120000743
申请日：2012-01-03
Applicant: 서울대학교산학협력단
CPC classification number: C12Q1/6883 , C12Q2600/158 , G01N33/6893 , G01N2800/042 , G01N2800/164 , G01N2800/50 , G01N2800/60 , G01N33/5302
Abstract: PURPOSE: A marker for early diagnosis of diabetic retinopathy (DR) is provided to early diagnose DR and to significantly predict or understand DR progression by measuring and comparing the expression level of a gene or a protein of which expression is reduced in a patient with DR. CONSTITUTION: A composition for diagnosis of DR contains an agent which measures mRNA or protein level of one or more genes selected from the group consisting of alpha-1-acid glycoprotein 2, alpha-1-antitrypsin, apolipoprotein A2, apolipoprotein A4, beta-2-glycoprotein 1, and gelsolin. A kit for diagnosing DR contains the composition. A method for providing information for diagnosing DR comprises the steps of: measuring the expression level of one or more genes or proteins selected from the group consisting of alpha-1-acid-glycoprotein 2, alpha-1-antitrypsin, apolipoprotein A2, apolipoprotein A4, beta-2-glycoprotein 1, and gelsolin in a biological sample; and comparing the expression level with the expression level of a control group sample.
Abstract translation: 目的：提供早期诊断糖尿病性视网膜病变（DR）的标志物，以早期诊断DR，并通过测量和比较DR患者中表达降低的基因或蛋白质的表达水平来显着预测或了解DR进展 。 构成：用于诊断DR的组合物含有测定一种或多种选自下组的基因或蛋白质水平的试剂：α-1-酸糖蛋白2，α-1-抗胰蛋白酶，载脂蛋白A2，载脂蛋白A4，β- 2-糖蛋白1和凝溶胶蛋白。 用于诊断DR的试剂盒包含组合物。 提供用于诊断DR的信息的方法包括以下步骤：测量一种或多种选自α-1-酸 - 糖蛋白2，α-1-抗胰蛋白酶，载脂蛋白A2，载脂蛋白A4的基因或蛋白质的表达水平 ，β-2-糖蛋白1和凝溶胶蛋白; 并将表达水平与对照组样品的表达水平进行比较。
-
公开(公告)号：KR1020160043567A
公开(公告)日：2016-04-22
申请号：KR1020140137441
申请日：2014-10-13
Applicant: 서울대학교산학협력단
Abstract: 본발명은항암활성을갖는잠분추출물을함유하는항암조성물에관한것으로, 더욱상세하게는잠분추출물, 잠분추출물을분획하여얻은잠분분획물, 잠분분획물로부터분리되어수득되는화합물을포함하는항암조성물에관한것이다. 본발명에따른잠분추출물, 이를분획하여얻은잠분분획물, 또는이로부터분리되어수득되는화합물인보미폴리올(vomifoliol) 및스티그마스테롤(stigmasterol)은우수한암 세포증식억제능을나타내므로, 천연물유래의신규항암제로이용이가능하다.
Abstract translation: 本发明涉及含有具有抗癌活性的蚕排泄物提取物的抗癌组合物。 更具体地说，本发明涉及蚕排泄物提取物，通过分离蚕排泄物提取物而得到的蚕排泄物级分，以及含有通过分离蚕排泄物级分得到的化合物的抗癌组合物。 根据本发明，通过分离其获得的化合物，通过分离其获得的蚕排泄物提取物，将其分馏得到的蚕排泄物级分，或呕吐醇和豆甾醇，对癌细胞增殖具有优异的抑制能力，因此可用作新型抗癌剂 衍生自天然物质。
-
公开(公告)号：KR101599893B1
公开(公告)日：2016-03-07
申请号：KR1020140054752
申请日：2014-05-08
Applicant: 서울대학교산학협력단
Abstract: 본발명은매미껍질추출물및 이로부터분리된테아닌을포함하는항암조성물에관한것이다. 본발명에따른매미껍질추출물, 이를분획하여얻은매미껍질분획물, 또는이로부터분리되어수득되는화합물인테아닌은우수한암 세포증식억제능을나타내므로, 천연물유래의신규항암제로이용이가능하다.
-
公开(公告)号：KR101535014B1
公开(公告)日：2015-07-09
申请号：KR1020140029879
申请日：2014-03-13
Applicant: 서울대학교산학협력단
CPC classification number: B22F9/24 , B22F1/0025 , B22F2301/10 , B22F2304/05
Abstract: 알코올용매, 구리전구체및 계면활성제를포함한혼합용액을제공하는단계, 상기혼합용액을승온하여반응시키는단계, 및상기반응으로부터얻어진생성물을세척및 분리하여구리나노선을얻는단계를포함하는구리나노선의합성방법을제공한다.
Abstract translation: 提供一种铜纳米线的合成方法，其包括以下步骤：提供包含醇溶剂，铜前体和表面活性剂的混合溶液; 加热并使混合溶液反应; 并通过洗涤和分离从反应获得的产物获得铜纳米线。
-
-
-
-
-
-
-
-
-
Search Results
28
records
(took 0.022 seconds)
